Search DIAN Tissue Requests

In order to avoid the situation where two investigators study the same research question, please search our database to determine if your topic has already been studied. If you find that your topic or a related topic has already been submitted, you may wish to contact the investigator to inquire about his/her findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID # (e.g. DIAN-T1004), the full request has been submitted and is either approved, disapproved or in process.

Displaying 101 - 110 of 111

Investigator:

Ji Yeun Hur

Title:

Characterization of gamma-secretase complexes in fibroblasts and iPSCs from PS1 or PS2 FAD mutations

Date of Request:

06/27/2023

Status:

approved

ID:

DIAN-T2306

Aim 1:

Characterize gamma-secretase complexes in fibroblasts and iPSCs

Aim 2:

Characterize the gamma-secretase activity in fibroblasts and iPSCs

Investigator:

Sally Temple

Title:

Assessing neurovascular interactions due to ADRD mutations

Date of Request:

08/15/2023

Status:

approved

ID:

DIAN-T2307

Aim 1:

We will differentiate iPSCs with ADRD mutations versus controls into cerebral organoids and blood vessel cells. The goal is to examine the impact of the APP mutation on the organoids and blood vessel cells separately and interacting in a vascularized organoid.

Aim 2:

The vascularized organoids will be sectioned and stained for Abeta, p-tau and the staining in different cell types will be quantified.

Aim 3:

The conditioned medium produced by the vascularized organoids will be assessed for pathological markers and inflammatory factors.

Aim 4:

The vascularized organoids will be dissociated for single cell -omics studies.

Investigator:

Laurent Roybon

Title:

Models and therapies for Alzheimer's disease

Date of Request:

08/16/2023

Status:

approved

ID:

DIAN-T2308

Aim 1:

Generate humanized models of early and advanced AD cellular pathogenesis

Aim 2:

Use humanized models to explore a gene therapy for disease progression in AD

Investigator:

David Gate

Title:

Spatial transcriptomics on vaccinated AD brains

Date of Request:

09/18/2023

Status:

pending approval

ID:

DIAN-T2309

Aim 1:

Identify spatial transcriptomic changes associated with Aβ vaccination

Investigator:

Josef Penninger

Title:

Generation of human AD lymphatic vessels

Date of Request:

01/09/2024

Status:

approved

ID:

DIAN-T2401

Aim 1:

Generation of human lymphatic vessel organoids using AD iPSC lines

Aim 2:

scRNA sequencing and profiling of lymphatic AD iPSC-derived organoids

Aim 3:

Functional characterization of lymphatic AD organoids under microfluidic draining systems

Investigator:

Kenneth Shepard

Title:

Hybrid CMOS/Brain-Organoid Reservoir Computing

Date of Request:

04/25/2024

Status:

approved

ID:

DIAN-T2402

Aim 1:

Aim 1. Integration of organoids onto wireless CMOS multielectrode arrays (MEAs). This task is about getting the hardware working for a prototype CMOS-organoid processor. This will rely heavily on the existing BISC hardware, a wireless 65k channel neural interface device, which communicates with an external wireless relay station. The BISC hardware allows organoids to be cultured directly on top of the interface chips, which should improve the quality of the recording and stimulating interface

Aim 2:

Aim 2. Demonstrate hybrid CMOS-organoid reservoir computing with the MNIST benchmark.

Investigator:

Randall Bateman

Title:

Accuracy and value of mid-throughput technology for biomarker measurement in the context of DIAN

Date of Request:

05/07/2024

Status:

approved

ID:

DIAN-T2403

Aim 1:

Comparison of mid-throughput to one at a time measurements

Aim 2:

Comparison of mid-throughput to high-throughput measurements

Aim 3:

Non-inferiority assessment of mid-throughput performance to assess amyloid positivity

Investigator:

P. Gleeson

Title:

Impact of familial Alzheimer’s disease mutations on APP trafficking and processing, and neuronal function

Date of Request:

06/23/2024

Status:

approved

ID:

DIAN-T2404

Aim 1:

To compare the trafficking pathways of wild type APP and familial Swedish APP mutant in human iPSC derived neurons

Aim 2:

To define the role of the Golgi in the processing of the familial Swedish APP mutant in the secretory pathway of iPSC-derived neurons

Aim 4:

To assess the impact of Golgi fragmentation, mediated by APP processing, on neuronal function

Investigator:

Sally Temple

Title:

Human iPSC model of Cerebro-Vascular Interactions in ADRD

Date of Request:

07/09/2024

Status:

approved

ID:

DIAN-T2405

Aim 1:

Generate and optimize a human cerebro-vascular model of PSEN1 and APP mutation

Aim 2:

Validation of the PSEN1 and APP cerebro-vascular model, including measures of face, construct, and predictive validity

Investigator:

Professor Katie Lunnon

Title:

The first systematic study to identify miRNAs, and corresponding gene regulatory networks, which influence familial Alzheimer's disease manifestation

Date of Request:

08/08/2024

Status:

pending approval

ID:

DIAN-T2406

Aim 1:

To quantify miRNAs in FAD and control PFC samples, relating this to neuropathological and clinical assessments. This will allow us to identify miRNAs that are implicated in disease, and its clinical heterogeneity and compare to miRNA profiled in SAD.

Aim 2:

To explore the downstream effect of differential miRNA expression at both the transcriptional and protein levels in the same samples. This will allow us to identify downstream pathways and effectors that are altered in FAD as a result of miRNA alterations, including characterising novel transcripts.

Aim 3:

To identify the competing endogenous RNA networks that regulate the expression of disease-associated miRNAs. We will construct co-expression networks of nominated miRNAs with lncRNAs and circRNAs in the same samples identifying specific lncRNA and cirRNAs that act as upstream molecular sponges to regulate miRNA and subsequently gene/protein expression in FAD.

Aim 4:

To investigate other (non-RNA based) epigenetic mechanisms that regulate gene expression and their relationship to FAD-associated miRNA-mRNA pairs in the same samples. This will allow us to understand the complete epigenetic landscape regulating the expression of nominated genes in FAD.